Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and leukemia group B 40101

Lawrence N. Shulman, Constance T. Cirrincione, Donald A. Berry, Heather P. Becker, Edith A. Perez, Ruth O'Regan, Silvana Martino, James N. Atkins, Erica Mayer, Charles J. Schneider, Gretchen Kimmick, Larry Norton, Hyman Muss, Eric P. Winer, Clifford Hudis

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Fingerprint

Dive into the research topics of 'Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and leukemia group B 40101'. Together they form a unique fingerprint.

Medicine & Life Sciences